KCNH2 variants in a family with epilepsy and Long QT syndrome: a case report and literature review

Yu Zhou¹#, Nanya Hao¹#, Josemir W. Sander¹,², Xu Lin³, Weixi Xiong¹*, Dong Zhou¹*

1. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China; Institute of Brain Science and Brain-inspired technology of West China Hospital, Sichuan University, Chengdu, China
2. NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG; Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom & Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, Netherlands
3. Department of Neurology, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan, China.

Author list
Yu Zhou E-mail: zhouyu_1997@163.com
Nanya Hao E-mail: haony2013@163.com
Josemir W. Sander E-mail: j.sander@ucl.ac.uk, ORCID: 0000-0001-6041-9661
Xu Lin E-mail: 85055494@qq.com
Weixi Xiong E-mail: 502216168@qq.com, ORCID: 0000-0001-6835-8664
Dong Zhou E-mail: zhoudong66@yahoo.de, ORCID: 0000-0001-7101-4125

# These authors contributed equally

*Corresponding authors:
Weixi Xiong MD, Department of Neurology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, China. E-mail: 502216168@qq.com, ORCID: 0000-0001-6835-8664
Dong Zhou MD, Department of Neurology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, China. E-mail: dongzhou66@yahoo.de, Tel: +86-13980088088, ORCID: 0000-0001-5096-7023.

Title character count: 98
Abstract word count: 282
Text word count: 1,657
Tables: 2
Figures: 2
Supplementary materials: 1
Running title: KCNH2 variants with epilepsy and Long QT syndrome

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/epd2.20046

This article is protected by copyright. All rights reserved.
Competing interest: None concerning this work

Received July 23rd, 2022; Accepted March 12th, 2023

Abstract

Background Genes associated with Long QT syndromes (LQTS), such as KCNQ1, KCNH2, and SCN5A, are common causes of epilepsy. The Arg 744* variant of KCNH2 has been previously reported in people with epilepsy or LQTS, but none of these patients were reported to simultaneously suffer from epilepsy and LQTS.

Case study Here, we report the case of a family with epilepsy and cardiac disorders. The proband, a 25-year-old woman, experienced her first seizure at the age of seven. Video electroencephalograms (vEEGs) showed epileptic discharges. Her 24-hour dynamic electrocardiograms (ECGs) showed QTc prolongation. The proband’s mother, who is 50 years old, had her first generalized tonic-clonic seizure (GTCS) at the age of 18 years old. After she gave birth at the age of 25, the frequency of seizures increased, so antiepileptic therapy was initiated. When she was 28 years old, she complained of palpitations and syncope for the first time, and QTc prolongation was detected on her 24-hour dynamic ECGs. The proband’s grandmother also had complaints of palpitations and syncope at the age of 73. Her 24-hour dynamic ECGs indicated supraventricular arrhythmia, with the lowest heart rate being 41 bpm, so she agreed to a pacemaker. A KCNH2 Arg 744*
A pathogenic variant was found in both the proband and her mother.

**Conclusion** We report a *KCNH2* Arg 744* variant in a family with both epilepsy and LQTS. This study expands the clinical phenotype of the Arg 744* *KCNH2* pathogenic variant. In the context of channelopathies, because of the genetic susceptibility of the brain and the heart, the risk of comorbidity should be considered. This also indicates the importance of precise antiepileptic drug (AED) management and regular ECG monitoring for patients with channelopathies.

**Keywords:** seizure, *KCNH2* gene, LQTS, mutation, SUDEP

**Introduction**
Genes associated with Long QT syndrome (LQTS) are often found in patients with epilepsy. Most cases of LQTS are associated with five ion channel genes (potassium and sodium): *KCNQ1, KCNE1, KCNH2, KCNE2,* and *SCN5A* [1-6]. In a cohort study of sudden unexpected death in epilepsy (SUDEP), a high proportion of cases were associated with clinically relevant gene variants in cardiac arrhythmia, including *KCNQ1* (which leads to LQTS1), *KCNH2* (which leads to LQTS2), and *SCN5A* (which leads to LQTS3) [7]. LQTS is a cardiac disorder characterized by arrhythmias (specifically torsade de pointes and ventricular fibrillation), syncope, and sudden death [8, 9]. LQTS is now
recognized as an inherited arrhythmogenic disorder, and familial clustering has often been reported [8]. Variants in \textit{KCNQ1}, \textit{KCNH2}, and \textit{SCN5A} account for more than 70% of all LQTS cases, and transcripts from all three major LQTS genes have been detected in the human brain [10-12]. Channelopathies can lead to epilepsy and arrhythmias. In a retrospective study, epilepsy phenotypes were recorded in patients with LQTS1, LQTS2, and LQTS3 [13].

The \textit{KCNH2} gene, also known as the \textit{human ether-a-go-go-related gene} (hERG) and encoding the ERG1 potassium channel, is expressed in the hippocampus and frontal cortex [11]. Variants in \textit{KCNH2} have been reported to potentially affect both neuronal firing patterns and cardiac excitability, which can explain the epilepsy phenotype as well as LQTS [14].

Here, we report a family with epilepsy, LQTS, syncope, and cardiac arrhythmias carrying a \textit{KCNH2} Arg 744* (the "*" is defined as a termination codon) pathogenic variant. The same pathogenic variant was previously reported in one case in a SUDEP cohort, but the QT interval corrected for heart rate (QTc) was normal[7]. The \textit{KCNH2} Arg 744* pathogenic variant has also been previously reported in people with LQTS, but with no associated epilepsy [15, 16].
Case study

The proband (Fig. 1A, IV-1), a 25-year-old woman, experienced her first seizure at the age of seven. She had two main seizure types: generalized tonic-clonic seizures (GTCS) during sleep, usually lasting less than two minutes, and auras during her menstrual period or when getting a cold, such as palpitations and a sense of impending onset, approximately one to two times a month. The patient uses antiepileptic drugs (AEDs), which are a combination of levetiracetam (LEV), valproate (VPA), and clonazepam (CZP), and has been GTCS seizure-free for three years. An MRI of the brain revealed no significant lesions. Interictal video electroencephalograms (vEEGs) showed left-temporal spikes (Fig. 2A), and ictal vEEGs started with low-wave sharp waves and spikes that mingled with electromyographic artifacts (Fig. 2B). Her 24-hour dynamic electrocardiograms (ECGs) showed QTc prolongation (Figs. 2C and 2D). QT intervals were measured on ECGs, and QTc intervals were calculated using the Bazett formula, where $\text{QTc} = \frac{\text{QT}}{\sqrt{RR}}$ (RR = 60 divided by heart rate).

The proband’s mother (Fig. 1A, III-2), aged 50 years, had her first GTCS seizure at the age of 18. Antiepileptic therapy was not initiated because the seizures were infrequent. However, after she gave birth at the age of 25, the frequency of seizures increased, and antiepileptic therapy with phenytoin (PHT) and oxcarbazepine (OXC) was initiated at her local hospital. When she was 28
years old, she complained of palpitations and syncope for the first time, and QTc prolongation was detected on her 24-hour dynamic ECGs two years later (Fig. 2D). She became seizure-free after switching AEDs to valproate (VPA) and carbamazepine (CZP), but palpitations and dizziness occasionally occurred, especially with high-intensity exercise.

The proband’s grandmother (Fig. 1A, II-2) complained of palpitations and syncope when she was 73. Her 24-hour dynamic ECGs indicated supraventricular arrhythmia with the lowest heart rate of 41 bpm, and she agreed to a pacemaker.

Considering the young patient’s family history, blood samples were collected from the patient and her parents after obtaining informed consent. Trio whole exome sequencing was performed using the chip capture probe of the IDT XGen Exome Research Panel V2.0 and the strategy of the Illumina NovaSeq 6000 PE150 with high-throughput sequencing technology. Three steps were included in the sequencing: mutation screening with high-throughput sequencing, genetic data analysis with bioinformatics and clinical information, and validation of suspected pathogenic mutations by Sanger sequencing. High-throughput whole mitochondrial genome sequencing was also performed to identify potential genetic causes; however, no pathogenic variants were found. A heterozygous variant of KCNH2 [c.2230 (exon9) C>T, p. Arg744Ter,
416, NM_000238, rs189014161] was found. The same variant was detected in the patient’s mother. According to the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, we classified the KCNH2 variant as pathogenic [17].

Discussion

We reviewed the literature on people with epilepsy carrying KCNH2 variants (Table 1) and found a high proportion of sudden, unexpected deaths. Nearly all patients had prolonged QTc, and epileptic discharges on EEG were found in most patients. Although the KCNH2 Arg 744* variant has been previously reported in patients with epilepsy or LQTS, none of these cases had a dual phenotype of epilepsy and LQTS (Table 2). As shown in Table 2, two studies reported sudden death among affected people, indicating that the gene variant has a high associated risk [7, 13, 15, 16, 18-29].

Here, we report a family with a KCNH2 Arg 744* pathogenic variant presenting with both epilepsy and LQTS. The same variant was previously reported in patients with epilepsy or LQTS, but none of these cases had a dual phenotype of epilepsy and LQTS [7, 15, 16]. To the best of our knowledge, this is the first case of a patient with a KCNH2 Arg 744* pathogenic variant presenting with both epilepsy and LQTS. The KCNH2 gene, encoding the ERG1 potassium channel, was originally isolated from a hippocampal cDNA library [30]. ERG1
channels are members of the ERG channel family and are voltage-gated channels. During depolarization, ERG channels quickly turn into an inactivated state, thereby suppressing the current at depolarized potentials. Upon repolarization, ERG channels quickly recover from the inactivated state but, owing to the slow deactivation time course, remain in a conductive state and diminish electrical activity during prolonged stimuli. Unique current profile of the ERG channels contributes to regulation of neuronal action potential firing frequency, spike frequency adaptation, and resting membrane potential [31]. ERG potassium channels expressed in various tissues, many of which are linked to disease [32]. ERG potassium channels are also widely expressed in the brain, where they contribute to regulating the frequency and discharge stability of neurons [33]. Blockade of ERG potassium channels in the hippocampus increases potassium concentrations extraneuronally [34], and such changes are epileptogenic [35]. The variant reported here because they may affect both neuronal firing patterns and cardiac excitability, which could explain both the epilepsy phenotype and LQTS [14]. LQTS2 patients with epilepsy have a higher prevalence and risk of arrhythmias than those without epilepsy, which partly depends on the shared genetic susceptibility between epilepsy and arrhythmia, in which channelopathies play a major role [18, 36]. Kohli, U., C. Ravishankar, and D. Nordli reported a case of KCNT1 mutation associated with epilepsy, systemic-to-pulmonary artery "collateralopathy," and intermittent QTc prolongation [37]. Although KCNT1 mutations are known to be
more common in epilepsy, the risk of heart disorders should be considered due to the genetic susceptibility of the heart. As mentioned above, because ERG potassium channels are expressed in numerous tissues, the pathogenicity of ERG potassium channels in different tissues and organs should be considered, as is the case for other channelopathies.

Young adults with epilepsy have a 24-fold increased risk of sudden death [38]. SUDEP is the most common cause of premature epilepsy-related mortality [39]. Moreover, inherited heart disease may also be a significant risk factor for SUDEP [40]. One study considered LQT+, type of LQTS, LQTS2 variant domain, QTc duration, and female sex as important factors for predicting epilepsy susceptibility [18], and so attention to these markers has the potential to reduce morbidity and SUDEP in young individuals with epilepsy. It should be emphasized that complete seizure freedom is the best way to reduce the risk of SUDEP, which in most cases can be achieved with the optimal use of AEDs.

Some AEDs, such as PHT, phenobarbital (PB), and lamotrigine (LTG), should be avoided in patients with LQTS. Although these drugs are not classified as medications associated with an increased risk of torsade de pointes on the CredibleMeds list [41], studies suggest an increased risk of arrhythmia and SUDEP with these drugs. For example, a previous study demonstrated that PHT and PB can inhibit potassium ion currents, which might be clinically
relevant to the risk of arrhythmia and SUDEP [42]. Further, a clinical cohort study showed that sodium channel blocker AEDs (e.g., PHT) were associated with an increased risk of cardiac events in participants with QTc prolongation, specifically LQTS2 [43]. LTG has been shown to block potassium ion currents [44], but a study of the effects of LTG on the QTc interval in healthy subjects found no significant increase in the QTc interval [45]. However, a case-control study of female patients with epilepsy showed that the incidence of SUDEP was significantly higher among those who were being treated with LTG than among those who were not [46]. Therefore, comorbidities should be considered when prescribing AEDs. It is worth noting that the proband’s mother complained of palpitations and syncope for the first time after taking PHT, but it was difficult to prove whether it was due to AEDs or the natural progression of the disease.

**Conclusion**

Here, we report a *KCNH2* Arg 744* pathogenic variant in a family with both epilepsy and LQTS, thus expanding the clinical phenotype associated with this variant. The co-occurrence of epilepsy and LQTS underscores the importance of considering the risk of comorbidity due to the genetic susceptibility of both the brain and the heart in channelopathies. Our findings also highlight the importance of precise AED management and regular ECG monitoring in patients with channelopathies.
Declarations

Acknowledgments

We are thankful to the patient and her family for their cooperation.

JWS is based at NIHR University College London Hospitals Biomedical Research Centre, which receives a proportion of funding from the UK Department of Health’s Research Centres funding scheme. He receives research support from the Marvin Weil Epilepsy Research Fund, the UK Epilepsy Society, and the Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, Netherlands.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81901327,81801294,81871017). The Post-Doctor Research Project of West China Hospital (No. 2019HXBH080). International Cooperation Project, Sichuan Science and Technology Department (2021YFH0141), and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2017305, ZYGD20011).

Availability of Data and Materials
Anonymized data will be shared by reasonable requests from any qualified investigator to the corresponding author.

Authors’ Contributions
YZ and NY were responsible for the follow-up of the patient. YZ, NY and WX prepared the first draft with all other authors’ feedback. YZ and NY were involved in collecting and managing data. JWS revised the manuscript and provided critical intellectual input. All authors read and approved the final manuscript.

Ethics Approval and Consent to Participate
The Ethics Board of West China Hospital, Sichuan University (approval 2019[48]) approved the study.
References


29. Partemi, S., et al., \textit{Loss-of-function KCNH2 mutation in a family with long QT


**Key points**

- This article reported a family with a KCNH2 Arg 744* pathogenic variant manifested epilepsy and LQTS.

- The KCNH2 gene encodes ERG1 potassium channel, which is expressed in
the brain and heart and can cause epilepsy and arrhythmias.

- People with epilepsy and LQTS should avoid some AEDs, such as PHT, phenobarbital (PB) and lamotrigine (LTG).

- Precise AEDs management and regular ECG monitoring are important for patients with epilepsy and LQTS.

TEST YOURSELF

1. For people with epilepsy, if their ECGs indicate arrhythmias, such as bradycardia, AV conduction blocks and QT prolongation, what kind of AEDs should be avoided?

2. What channelopathies genes are associated with epilepsy and arrhythmias?

Literature review
**Figure 1.**

A) Pedigree of the studied family: The arrow indicates the proband. Circles and squares represent females and males, respectively. Red, green, brown and blue represent subjects with epilepsy, QTc prolongation, syncope and cardiac arrhythmias, respectively. Cross represents dead subject. B) DNA sequence analysis: A C to T transition in $KCNH2$ R744* potassium channel gene was found in the proband and her mother.

**Figure 2.**

A) Interictal vEEGs (10uV/mm, 30mm/sec) of the proband showed left-temporal spikes. B) Ictal vEEGs (10uV/mm, 30mm/sec) of the proband started with low-wave sharp waves and spikes, mingled with electromyographic artifacts. C) 24-hour dynamic ECGs of the proband (25
mm/s, 10mm/mV), heart rate 73 bpm, corrected QT (QTc) interval of 485 ms. D) 24-hour
dynamic ECGs of the proband (25 mm/s, 10mm/mV) with the fastest heart rate of 147 bpm,
corrected QT (QTc) interval of 563 ms. E) 24-hour dynamic ECGs of the proband’s mother (25
mm/s, 10mm/mV), heart rate 67 bpm, corrected QT (QTc) interval of 550 ms.
**Literature review**

**Table 1** Clinical features of patients with epilepsy carrying KCNH2 gene variant

<table>
<thead>
<tr>
<th>References</th>
<th>Epilepsy with KCNH2 variant case No./total</th>
<th>Family history of epilepsy</th>
<th>Age at seizure onset (range or minimum age)</th>
<th>Sudden death of affected patients</th>
<th>Age of death of affected patients (range or minimum age)</th>
<th>Epileptiform EEGs</th>
<th>ECGs</th>
<th>Computer imaging (CT/MRI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partemi, S., et al. [29]</td>
<td>4 affected family members</td>
<td>+</td>
<td>13</td>
<td>+</td>
<td>18</td>
<td>QT prolongation</td>
<td>Normal</td>
<td>CT/MRI</td>
</tr>
<tr>
<td>Auerbach, D.S., et al. [18]</td>
<td>75/1901</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>LQTS (NA)</td>
<td>NA</td>
<td>CT/MRI</td>
</tr>
<tr>
<td>Zarroli, K. and H. Querfurth [19]</td>
<td>1/1</td>
<td>+</td>
<td>26</td>
<td>–</td>
<td>–</td>
<td>QT prolongation</td>
<td>slight prominence in the right temporal ventricular horn</td>
<td></td>
</tr>
<tr>
<td>Tu, E., et al. [21]</td>
<td>5/68</td>
<td>NA</td>
<td>NA</td>
<td>+</td>
<td>39</td>
<td>NA</td>
<td>NA</td>
<td>CT/MRI</td>
</tr>
<tr>
<td>Omichi, C., Y. Momose, and S. Kitahara [22]</td>
<td>7 affected family members</td>
<td>+</td>
<td>20</td>
<td>+</td>
<td>Between 20 to 40</td>
<td>QT prolongation</td>
<td>Normal</td>
<td>CT/MRI</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Age</td>
<td>Gender</td>
<td>Family History</td>
<td>QT Prolongation</td>
<td>Outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
<td>-----</td>
<td>--------</td>
<td>----------------</td>
<td>-----------------</td>
<td>--------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anderson, J.H., et al. [23]</td>
<td>7/610</td>
<td>NA</td>
<td>±8</td>
<td>NA</td>
<td>NA</td>
<td>QT prolongation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olberg, H.K., et al. [26]</td>
<td>1/1</td>
<td>NA</td>
<td>10+</td>
<td>–</td>
<td>–</td>
<td>QT prolongation NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jorge, C., et al. [27]</td>
<td>1/1</td>
<td>+</td>
<td>2</td>
<td>+</td>
<td>NA</td>
<td>QT prolongation Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ichikawa, M., et al. [28]</td>
<td>4 affected family members</td>
<td>+</td>
<td>26</td>
<td>+</td>
<td>30</td>
<td>QT prolongation NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EEGs, electroencephalograms; ECGs, electrocardiograms; NA, not available; LQTS, long QT syndrome; HS, hippocampal sclerosis.
<table>
<thead>
<tr>
<th>References</th>
<th>Arg 744* variant case</th>
<th>Seizure</th>
<th>LQT/S</th>
<th>Family history</th>
<th>Sudden death of affected patients</th>
<th>age of death of affected patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaplinger, J.D., et al. [16]</td>
<td>4/2500</td>
<td>NA</td>
<td>+</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Current study</td>
<td>6 affected family</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

NA, not available; LQT/S, long QT syndrome